WuXi Considers Selling US and European Units Amid BIOSECURE Act Impact

WuXi AppTec and WuXi Biologics are actively responding to the potential implications of the BIOSECURE Act by considering the sale of certain U.S. and European business units. WuXi AppTec is contemplating the divestiture of its Advanced Therapies manufacturing unit in Philadelphia, while WuXi Biologics evaluates selling some European production sites[1][2]. The Act, which has been passed by the U.S. House and is pending Senate approval, seeks to curb collaborations between U.S. biopharma companies and Chinese entities, thus posing significant operational challenges and impacting drug supply chains[1]. Despite these pressures, WuXi Biologics has reported the addition of 61 new projects in early 2024, although European business momentum is tempered by contracting concerns[2].